SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as discussions erupt over former President Trump's assertive policy stances, including controversial proposals regarding Greenland's future and Venezuela's oil sector, alongside domestic economic initiatives. Community dialogue is highly polarized, with advocates lauding decisive leadership while detractors voice concerns about potential global instability and authoritarianism.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is actively trending amidst a surge of community mentions and engagement, reflecting both strong bullish sentiment and ongoing technical discussions. Many compare it to Bitcoin, highlighting its potential as a faster, cheaper 'digital silver' for transactions, though some long-term holders express skepticism about its performance.

The White Whale

WHITEWHALE CRYPTO is experiencing significant community attention with relentless trading volume, attracting discussions as a potential new standard in Solana-based meme coins. Holders are actively noting massive accumulation and growing numbers of participants, highlighting unique tokenomics, including substantial locked liquidity, which draws comparisons to other high-flying meme projects.

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.

Novabay Pharmaceuticals Inc

Novabay Pharmaceuticals Inc. is a major talking point due to its volatile trading and a significant special cash dividend that created complex 'due bills' trading conditions. Community interest is high around the company's strategic pivot into blockchain-based assets, fueling speculation of a massive short squeeze while also drawing skepticism regarding its fundamental value given the dramatic shift from its pharmaceutical roots.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is currently trending amid a fervent debate over a proposed credit card rate cap, with the community sharply divided on whether it poses a significant threat or could unlock new opportunities for AI-driven lending. Investor attention is also focused on the company's high short interest, fueling speculation of a potential squeeze as the market anticipates favorable announcements regarding balance sheet funding and strong upcoming earnings in a declining rate environment.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors keenly await its FDA Biologics License Application (BLA) resubmission for Deramiocel, following robust Phase 3 HOPE-3 data for Duchenne Muscular Dystrophy. Bulls express strong conviction in the "stat sig" results, anticipating accelerated approval and significant upside, yet community dialogue also highlights growing impatience over the delayed submission and concerns among some about potential regulatory scrutiny, driving current market fluctuations. This tension between strong data and perceived communication delays fuels active discussion surrounding the company's future in the DMD therapeutic landscape.

Polygon

Polygon (POL) is trending with high community enthusiasm, fueled by recent announcements of robust on-chain revenue growth and increased token burning, creating scarcity. Investors are actively discussing its perceived undervaluation compared to rival platforms and anticipating significant market gains driven by its expanding utility in payments and institutional integrations. There's also a notable community conversation regarding a potential return to its familiar MATIC ticker for enhanced brand identity.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie is a key topic after delivering strong Q3 earnings, raising its outlook, and boosting its dividend, even as the stock experienced unusual volatility following the news. Investors are focused on the robust growth of Skyrizi and Rinvoq in mitigating Humira's market shift, amidst continuous community speculation around AbbVie's strategic M&A moves in the dynamic biopharmaceutical landscape.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is a hot topic following a substantial $1 billion direct offering to a single institutional investor at a premium, with warrants priced significantly above current trading, signaling strong confidence in its long-term growth. The community is actively discussing how this capital infusion positions Ondas for major acquisitions and contract wins in critical areas like demining in Ukraine, border security, and defense robotics. Many anticipate accelerated expansion and further strategic announcements ahead of upcoming investor events.

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Cullinan Therapeutics Inc

Cullinan Oncology Inc

Cullinan Therapeutics (CGEM) is trending following positive clinical data for its leukemia therapy CLN-049, which recently received FDA Fast Track designation, and promising results for its lung cancer drug Zipalertinib. The company's strategic expansion into autoimmune diseases with its CD19xCD3 T-cell engager, CLN-978, is also a significant catalyst, supported by an oversubscribed private placement and strong institutional backing. The community is actively discussing its undervalued status and pipeline potential, with notable options activity reflecting optimistic sentiment for future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
